{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:54Z","timestamp":1787003934061,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The protozoan parasite\n                    <jats:italic>Trypanosoma brucei<\/jats:italic>\n                    causes the fatal illness human African trypanosomiasis (HAT). Standard of care medications currently used to treat HAT have severe limitations, and there is a need to find new chemical entities that are active against infections of\n                    <jats:italic>T<\/jats:italic>\n                    .\n                    <jats:italic>brucei<\/jats:italic>\n                    . Following a \u201cdrug repurposing\u201d approach, we tested anti-trypanosomal effects of carbazole-derived compounds called \u201cCuraxins\u201d.\n                    <jats:italic>In vitro<\/jats:italic>\n                    screening of 26 compounds revealed 22 with nanomolar potency against axenically cultured bloodstream trypanosomes. In a murine model of HAT, oral administration of compound\n                    <jats:bold>1<\/jats:bold>\n                    cured the disease. These studies established\n                    <jats:bold>1<\/jats:bold>\n                    as a lead for development of drugs against HAT. Pharmacological time-course studies revealed the primary effect of\n                    <jats:bold>1<\/jats:bold>\n                    to be concurrent inhibition of mitosis coupled with aberrant licensing of S-phase entry. Consequently, polyploid trypanosomes containing 8C equivalent of DNA per nucleus and three or four kinetoplasts were produced. These effects of\n                    <jats:bold>1<\/jats:bold>\n                    on the trypanosome are reminiscent of \u201cmitotic slippage\u201d or endoreplication observed in some other eukaryotes.\n                  <\/jats:p>","DOI":"10.1038\/srep32083","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T07:26:28Z","timestamp":1472196388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis"],"prefix":"10.1038","volume":"6","author":[{"given":"Sarah M.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Purmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo","family":"Mensa-Wilmot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"BFsrep32083_CR1","unstructured":"WHO. Control and surveillance of human African trypanosomiasis. WHO Technical Report Series 984, 1\u2013237 (2013)."},{"key":"BFsrep32083_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/s0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun, R., Blum, J., Chappuis, F. & Burri, C. Human African trypanosomiasis. Lancet 375, 148\u2013159, 10.1016\/s0140-6736(09)60829-1 (2010).","journal-title":"Lancet"},{"key":"BFsrep32083_CR3","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/aac.00246-11","volume":"55","author":"M Kaiser","year":"2011","unstructured":"Kaiser, M. et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 55, 5602\u20135608, 10.1128\/aac.00246-11 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep32083_CR4","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","volume":"5","author":"RT Jacobs","year":"2011","unstructured":"Jacobs, R. T. et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 5, e1151, 10.1371\/journal.pntd.0001151 (2011).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep32083_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00001432-200412000-00009","volume":"17","author":"J Jannin","year":"2004","unstructured":"Jannin, J. & Cattand, P. Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 17, 565\u2013571 (2004).","journal-title":"Curr Opin Infect Dis"},{"key":"BFsrep32083_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.coph.2012.05.001","volume":"12","author":"P Maser","year":"2012","unstructured":"Maser, P. et al. Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 12, 562\u2013566, 10.1016\/j.coph.2012.05.001 (2012).","journal-title":"Curr Opin Pharmacol"},{"key":"BFsrep32083_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0166-6851(02)00282-7","volume":"126","author":"MH Gelb","year":"2003","unstructured":"Gelb, M. H. et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 126, 155\u2013163 (2003).","journal-title":"Mol Biochem Parasitol"},{"key":"BFsrep32083_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673\u2013683, 10.1038\/nrd1468 (2004).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep32083_CR9","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1128\/aac.01691-13","volume":"58","author":"R Behera","year":"2014","unstructured":"Behera, R., Thomas, S. M. & Mensa-Wilmot, K. New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs. Antimicrob Agents Chemother 58, 2202\u20132210, 10.1128\/aac.01691-13 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep32083_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.4155\/fmc.11.92","volume":"3","author":"MP Pollastri","year":"2011","unstructured":"Pollastri, M. P. & Campbell, R. K. Target repurposing for neglected diseases. Future medicinal chemistry 3, 1307\u20131315, 10.4155\/fmc.11.92 (2011).","journal-title":"Future medicinal chemistry"},{"key":"BFsrep32083_CR11","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1021\/jm400349k","volume":"56","author":"G Patel","year":"2013","unstructured":"Patel, G. et al. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. J Med Chem 56, 3820\u20133832, 10.1021\/jm400349k (2013).","journal-title":"J Med Chem"},{"key":"BFsrep32083_CR12","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1021\/jm3011146","volume":"55","author":"AD Favia","year":"2012","unstructured":"Favia, A. D. et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase\/cyclooxygenase inhibitor. J Med Chem 55, 8807\u20138826, 10.1021\/jm3011146 (2012).","journal-title":"J Med Chem"},{"key":"BFsrep32083_CR13","doi-asserted-by":"publisher","first-page":"17010","DOI":"10.1073\/pnas.1213956109","volume":"109","author":"H De Jesus-Cortes","year":"2012","unstructured":"De Jesus-Cortes, H. et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 109, 17010\u201317015, 10.1073\/pnas.1213956109 (2012).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep32083_CR14","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1016\/j.bmc.2013.08.066","volume":"21","author":"HJ Yoon","year":"2013","unstructured":"Yoon, H. J. et al. Aminopropyl carbazole analogues as potent enhancers of neurogenesis. Bioorg Med Chem 21, 7165\u20137174, 10.1016\/j.bmc.2013.08.066 (2013).","journal-title":"Bioorg Med Chem"},{"key":"BFsrep32083_CR15","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1039\/c3cs60448a","volume":"43","author":"AA Pieper","year":"2014","unstructured":"Pieper, A. A., McKnight, S. L. & Ready, J. M. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev 43, 6716\u20136726, 10.1039\/c3cs60448a (2014).","journal-title":"Chem Soc Rev"},{"key":"BFsrep32083_CR16","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.3390\/molecules19079307","volume":"19","author":"C Saturnino","year":"2014","unstructured":"Saturnino, C. et al. N-alkyl carbazole derivatives as new tools for Alzheimer\u2019s disease: preliminary studies. Molecules 19, 9307\u20139317, 10.3390\/molecules19079307 (2014).","journal-title":"Molecules"},{"key":"BFsrep32083_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/scitranslmed.3002530","volume":"3","author":"AV Gasparian","year":"2011","unstructured":"Gasparian, A. V. et al. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Science translational medicine 3, 95\u201374, 10.1126\/scitranslmed.3002530 (2011).","journal-title":"Science translational medicine"},{"key":"BFsrep32083_CR18","doi-asserted-by":"publisher","first-page":"312ra176","DOI":"10.1126\/scitranslmed.aab1803","volume":"7","author":"DR Carter","year":"2015","unstructured":"Carter, D. R. et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science translational medicine 7, 312ra176, 10.1126\/scitranslmed.aab1803 (2015).","journal-title":"Science translational medicine"},{"key":"BFsrep32083_CR19","unstructured":"Incuron. A Phase I Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas. http:\/\/clinicaltrials.gov\/show\/NCT01905228. Date of Access: 2015 Dec 15 (2013)."},{"key":"BFsrep32083_CR20","unstructured":"Tucker, J. et al. Inventors; Cleveland BioLabs, Inc., assignee. Carbazole compounds and therapeutic uses of the compounds. World Patent WO 2010\/042445 A1. Apr 15 2010."},{"key":"BFsrep32083_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nrd2144","volume":"5","author":"S Nwaka","year":"2006","unstructured":"Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nature reviews. Drug discovery 5, 941\u2013955 (2006).","journal-title":"Nature reviews. Drug discovery"},{"key":"BFsrep32083_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0169-4758(94)90402-2","volume":"10","author":"H Hirumi","year":"1994","unstructured":"Hirumi, H. & Hirumi, K. Axenic culture of African trypanosome bloodstream forms. Parasitology Today 10, 80\u201384, 10.1016\/0169-4758(94)90402-2 (1994).","journal-title":"Parasitology Today"},{"key":"BFsrep32083_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0166-6851(01)00257-2","volume":"114","author":"S Leal","year":"2001","unstructured":"Leal, S. et al. Virulence of Trypanosoma brucei strain 427 is not affected by the absence of glycosylphosphatidylinositol phospholipase C. Mol Biochem Parasitol 114, 245\u2013247 (2001).","journal-title":"Mol Biochem Parasitol"},{"key":"BFsrep32083_CR24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1128\/AAC.34.6.1183","volume":"34","author":"CJ Bacchi","year":"1990","unstructured":"Bacchi, C. J. et al. Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother 34, 1183\u20131188 (1990).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep32083_CR25","doi-asserted-by":"publisher","first-page":"e56150","DOI":"10.1371\/journal.pone.0056150","volume":"8","author":"S Katiyar","year":"2013","unstructured":"Katiyar, S. et al. Lapatinib-binding protein kinases in the african trypanosome: identification of cellular targets for kinase-directed chemical scaffolds. PloS one 8, e56150, 10.1371\/journal.pone.0056150 (2013).","journal-title":"PloS one"},{"key":"BFsrep32083_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0001-706x(93)90100-p","volume":"54","author":"R Kaminsky","year":"1993","unstructured":"Kaminsky, R. & Brun, R. In vitro assays to determine drug sensitivities of African trypanosomes: a review. Acta Tropica 54, 279\u2013289, 10.1016\/0001-706x(93)90100-p (1993).","journal-title":"Acta Tropica"},{"key":"BFsrep32083_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","volume":"55","author":"W Huber","year":"1993","unstructured":"Huber, W. & Koella, J. C. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Tropica 55, 257\u2013261 (1993).","journal-title":"Acta Tropica"},{"key":"BFsrep32083_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/nsa.s78134","volume":"8","author":"SI Kaba","year":"2015","unstructured":"Kaba, S. I. & Egorova, E. M. In vitro studies of the toxic effects of silver nanoparticles on HeLa and U937 cells. Nanotechnology, science and applications 8, 19\u201329, 10.2147\/nsa.s78134 (2015).","journal-title":"Nanotechnology, science and applications"},{"key":"BFsrep32083_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0378-4274(80)90031-4","volume":"5","author":"B Ekwall","year":"1980","unstructured":"Ekwall, B. & Johansson, A. Preliminary studies on the validity of in vitro measurement of drug toxicity using HeLa cells. I. Comparative in vitro cytotoxicity of 27 drugs. Toxicology letters 5, 299\u2013307 (1980).","journal-title":"Toxicology letters"},{"key":"BFsrep32083_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/1087057114556236","volume":"20","author":"J Faria","year":"2015","unstructured":"Faria, J. et al. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei. Journal of biomolecular screening 20, 70\u201381, 10.1177\/1087057114556236 (2015).","journal-title":"Journal of biomolecular screening"},{"key":"BFsrep32083_CR31","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/AAC.36.12.2736","volume":"36","author":"CJ Bacchi","year":"1992","unstructured":"Bacchi, C. J. et al. Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrob Agents Chemother 36, 2736\u20132740 (1992).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep32083_CR32","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1128\/aac.00498-10","volume":"54","author":"B Nare","year":"2010","unstructured":"Nare, B. et al. Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis. Antimicrob. Agents Chemother. 54, 4379\u20134388, 10.1128\/aac.00498-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep32083_CR33","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/IAI.67.6.3128-3132.1999","volume":"67","author":"S Magez","year":"1999","unstructured":"Magez, S., Radwanska, M., Beschin, A., Sekikawa, K. & De Baetselier, P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 67, 3128\u20133132 (1999).","journal-title":"Infect Immun"},{"key":"BFsrep32083_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0001-706X(95)00109-R","volume":"60","author":"B Bouteille","year":"1995","unstructured":"Bouteille, B. et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop 60, 73\u201380 (1995).","journal-title":"Acta Trop"},{"key":"BFsrep32083_CR35","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1371\/journal.pntd.0000678","volume":"4","author":"C Worthen","year":"2010","unstructured":"Worthen, C., Jensen, B. C. & Parsons, M. Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage Trypanosoma brucei . PLoS Negl Trop Dis 4, e678, 10.1371\/journal.pntd.0000678 (2010).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep32083_CR36","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1371\/journal.pntd.0000440","volume":"3","author":"S Nwaka","year":"2009","unstructured":"Nwaka, S. et al. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3, e440, 10.1371\/journal.pntd.0000440 (2009).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep32083_CR37","doi-asserted-by":"publisher","first-page":"e1001226","DOI":"10.1371\/journal.ppat.1001226","volume":"6","author":"A Roy Chowdhury","year":"2010","unstructured":"Roy Chowdhury, A. et al. The killing of African trypanosomes by ethidium bromide. PLoS Pathog 6, e1001226, 10.1371\/journal.ppat.1001226 (2010).","journal-title":"PLoS Pathog"},{"key":"BFsrep32083_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0167-6296(02)00126-1","volume":"22","author":"JA DiMasi","year":"2003","unstructured":"DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. Journal of health economics 22, 151\u2013185, 10.1016\/s0167-6296(02)00126-1 (2003).","journal-title":"Journal of health economics"},{"key":"BFsrep32083_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijpddr.2012.02.002","volume":"2","author":"T Bowling","year":"2012","unstructured":"Bowling, T., Mercer, L., Don, R., Jacobs, R. & Nare, B. Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis. International journal for parasitology. Drugs and drug resistance 2, 262\u2013270, 10.1016\/j.ijpddr.2012.02.002 (2012).","journal-title":"International journal for parasitology. Drugs and drug resistance"},{"key":"BFsrep32083_CR40","doi-asserted-by":"publisher","first-page":"e1932","DOI":"10.1371\/journal.pntd.0001932","volume":"6","author":"M De Rycker","year":"2012","unstructured":"De Rycker, M. et al. A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes. PLoS Negl Trop Dis 6, e1932, 10.1371\/journal.pntd.0001932 (2012).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep32083_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molbiopara.2007.01.017","volume":"153","author":"TC Hammarton","year":"2007","unstructured":"Hammarton, T. C. Cell cycle regulation in Trypanosoma brucei. Mol Biochem Parasitol 153, 1\u20138, 10.1016\/j.molbiopara.2007.01.017 (2007).","journal-title":"Mol Biochem Parasitol"},{"key":"BFsrep32083_CR42","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1128\/ec.00145-12","volume":"11","author":"Z Li","year":"2012","unstructured":"Li, Z. Regulation of the cell division cycle in Trypanosoma brucei. Eukaryotic cell 11, 1180\u20131190, 10.1128\/ec.00145-12 (2012).","journal-title":"Eukaryotic cell"},{"key":"BFsrep32083_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1021\/ja308733u","volume":"135","author":"L Bertolacci","year":"2013","unstructured":"Bertolacci, L. et al. A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. Journal of the American Chemical Society 135, 22\u201325, 10.1021\/ja308733u (2013).","journal-title":"Journal of the American Chemical Society"},{"key":"BFsrep32083_CR44","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1073\/pnas.0805326105","volume":"105","author":"FM Boeckler","year":"2008","unstructured":"Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105, 10360\u201310365, 10.1073\/pnas.0805326105 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep32083_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1158\/1940-6207.capr-11-0529","volume":"5","author":"IE Koman","year":"2012","unstructured":"Koman, I. E. et al. Targeting FACT complex suppresses mammary tumorigenesis in Her2\/neu transgenic mice. Cancer prevention research (Philadelphia, Pa.) 5, 1025\u20131035, 10.1158\/1940-6207.capr-11-0529 (2012).","journal-title":"Cancer prevention research (Philadelphia, Pa.)"},{"key":"BFsrep32083_CR46","first-page":"169","volume":"1","author":"K Nakamura","year":"2002","unstructured":"Nakamura, K. et al. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther 1, 169\u2013175 (2002).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep32083_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1124\/jpet.302.1.352","volume":"302","author":"BA Shapiro","year":"2002","unstructured":"Shapiro, B. A., Ray, S., Jung, E., Allred, W. T. & Bollag, W. B. Putative conventional protein kinase C inhibitor Godecke 6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3.4-c)-carbazole] stimulates transglutaminase activity in primary mouse epidermal keratinocytes. The Journal of pharmacology and experimental therapeutics 302, 352\u2013358 (2002).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"BFsrep32083_CR48","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ejmech.2007.07.016","volume":"43","author":"JB Smaill","year":"2008","unstructured":"Smaill, J. B. et al. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. European journal of medicinal chemistry 43, 1276\u20131296, 10.1016\/j.ejmech.2007.07.016 (2008).","journal-title":"European journal of medicinal chemistry"},{"key":"BFsrep32083_CR49","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.07.040","volume":"158","author":"G Wang","year":"2014","unstructured":"Wang, G. et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 1324\u20131334, 10.1016\/j.cell.2014.07.040 (2014).","journal-title":"Cell"},{"key":"BFsrep32083_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.chembiol.2014.02.009","volume":"21","author":"Z Yin","year":"2014","unstructured":"Yin, Z. et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chemistry & biology 21, 481\u2013487, 10.1016\/j.chembiol.2014.02.009 (2014).","journal-title":"Chemistry & biology"},{"key":"BFsrep32083_CR51","doi-asserted-by":"publisher","first-page":"20519","DOI":"10.1074\/jbc.M312862200","volume":"279","author":"X Tu","year":"2004","unstructured":"Tu, X. & Wang, C. C. The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion. J Biol Chem 279, 20519\u201320528, 10.1074\/jbc.M312862200 (2004).","journal-title":"J Biol Chem"},{"key":"BFsrep32083_CR52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2958.2009.06657.x","volume":"72","author":"N Jetton","year":"2009","unstructured":"Jetton, N. et al. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol Microbiol 72, 442\u2013458, 10.1111\/j.1365-2958.2009.06657.x (2009).","journal-title":"Mol Microbiol"},{"key":"BFsrep32083_CR53","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/j.1365-2958.2008.06493.x","volume":"70","author":"ME Lindsay","year":"2008","unstructured":"Lindsay, M. E., Gluenz, E., Gull, K. & Englund, P. T. A new function of Trypanosoma brucei mitochondrial topoisomerase II is to maintain kinetoplast DNA network topology. Mol Microbiol 70, 1465\u20131476, 10.1111\/j.1365-2958.2008.06493.x (2008).","journal-title":"Mol Microbiol"},{"key":"BFsrep32083_CR54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/sj.onc.1204126","volume":"20","author":"H Tsuiki","year":"2001","unstructured":"Tsuiki, H. et al. Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene 20, 420\u2013429, 10.1038\/sj.onc.1204126 (2001).","journal-title":"Oncogene"},{"key":"BFsrep32083_CR55","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.tplants.2011.07.001","volume":"16","author":"L De Veylder","year":"2011","unstructured":"De Veylder, L., Larkin, J. C. & Schnittger, A. Molecular control and function of endoreplication in development and physiology. Trends in plant science 16, 624\u2013634, 10.1016\/j.tplants.2011.07.001 (2011).","journal-title":"Trends in plant science"},{"key":"BFsrep32083_CR56","doi-asserted-by":"publisher","first-page":"e15701","DOI":"10.1371\/journal.pone.0015701","volume":"5","author":"J Zanet","year":"2010","unstructured":"Zanet, J. et al. A mitosis block links active cell cycle with human epidermal differentiation and results in endoreplication. PloS One 5, e15701, 10.1371\/journal.pone.0015701 (2010).","journal-title":"PloS One"},{"key":"BFsrep32083_CR57","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2004-02-0419","volume":"104","author":"AE Geddis","year":"2004","unstructured":"Geddis, A. E. & Kaushansky, K. Megakaryocytes express functional Aurora-B kinase in endomitosis. Blood 104, 1017\u20131024, 10.1182\/blood-2004-02-0419 (2004).","journal-title":"Blood"},{"key":"BFsrep32083_CR58","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood.V91.10.3711","volume":"91","author":"N Vitrat","year":"1998","unstructured":"Vitrat, N. et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 91, 3711\u20133723 (1998).","journal-title":"Blood"},{"key":"BFsrep32083_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1128\/AAC.46.3.797-807.2002","volume":"46","author":"JJ Brendle","year":"2002","unstructured":"Brendle, J. J. et al. Antileishmanial activities of several classes of aromatic dications. Antimicrobial agents and chemotherapy 46, 797\u2013807 (2002).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep32083_CR60","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1021\/ml400015f","volume":"4","author":"J Molette","year":"2013","unstructured":"Molette, J. et al. Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties. ACS medicinal chemistry letters 4, 1037\u20131041, 10.1021\/ml400015f (2013).","journal-title":"ACS medicinal chemistry letters"},{"key":"BFsrep32083_CR61","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1128\/aac.04704-14","volume":"59","author":"J Erath","year":"2015","unstructured":"Erath, J. et al. Small-molecule xenomycins inhibit all stages of the Plasmodium life cycle. Antimicrob Agents Chemother 59, 1427\u20131434, 10.1128\/aac.04704-14 (2015).","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1038\/srep40565","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32083","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:10:37Z","timestamp":1672881037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,31]]}},"alternative-id":["BFsrep32083"],"URL":"https:\/\/doi.org\/10.1038\/srep32083","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]},"assertion":[{"value":"11 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper. In addition, the version of this Article previously published contained a lower resolution image for Figure 1. This has now been corrected in the PDF and HTML version of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32083"}}